MEDIMMUNE INC /DE Form 8-K April 12, 2007

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

# FORM 8-K

**CURRENT REPORT** 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)

April 12, 2007

# MedImmune, Inc.

(Exact name of registrant as specified in its charter)

**Delaware**(State or other jurisdiction of incorporation or organization)

0-19131

(Commission File No.)

52-1555759

(I.R.S. Employer Identification No.)

One MedImmune Way, Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code (301) 398-0000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01 Other Events.

On April 12, 2007, MedImmune, Inc. (the Company ) issued a press release announcing that it was exploring possible strategic alternatives. A copy of the Company s press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No. Description

99.1 Press Release by MedImmune, Inc., dated April 12, 2007.

2

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MedImmune, Inc.

Date: April 12, 2007

By:

/s/ William C. Bertrand, Jr. Esq. William C. Bertrand Jr., Esq. Senior Vice President, General Counsel & Corporate Secretary

3

#### EXHIBIT INDEX

Exhibit

No. Description

99.1 Press Release by MedImmune, Inc., dated April 12, 2007.

4